NCT05273554 2026-01-12A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal AdenocarcinomaM.D. Anderson Cancer CenterPhase 1 Active not recruiting15 enrolled